<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079300</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000355151</org_study_id>
    <secondary_id>NCI-02-CC-0289</secondary_id>
    <secondary_id>3M-1454-IMIQ</secondary_id>
    <nct_id>NCT00079300</nct_id>
    <nct_alias>NCT00045851</nct_alias>
  </id_info>
  <brief_title>Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer</brief_title>
  <official_title>Double-Blind, Vehicle-Controlled Study to Evaluate Apoptosis in Basal Cell Carcinoma Treated With Aldara™ (Imiquimod) Cream, 5% Applied Once or Twice a Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Naval Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate&#xD;
      the immune system and stop tumor cells from growing.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating&#xD;
      patients with basal cell skin cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare levels of apoptosis in patients with basal cell skin cancer treated with vs&#xD;
           without imiquimod 5% cream.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare levels of apoptosis in patients treated with this drug on two different&#xD;
           administration schedules.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel-group study.&#xD;
&#xD;
      Patients undergo fine needle aspiration and punch biopsies of the target lesion. Patients are&#xD;
      then randomized to 1 of 8 treatment arms and begin therapy within 30 days after biopsy.&#xD;
&#xD;
        -  Arm I: Patients apply topical imiquimod to the target lesion once every 12 hours on days&#xD;
           1 and 2 for a total of 4 doses.&#xD;
&#xD;
        -  Arm II: Patients apply topical placebo to the target lesion once every 12 hours on days&#xD;
           1 and 2 for a total of 4 doses.&#xD;
&#xD;
        -  Arm III: Patients apply topical imiquimod to the target lesion once every 24 hours on&#xD;
           days 1-4 for a total of 4 doses.&#xD;
&#xD;
        -  Arm IV: Patients apply topical placebo to the target lesion once every 24 hours on days&#xD;
           1-4 for a total of 4 doses.&#xD;
&#xD;
        -  Arm V: Patients apply topical imiquimod to the target lesion once every 12 hours on days&#xD;
           1-4 for a total of 8 doses.&#xD;
&#xD;
        -  Arm VI: Patients apply topical placebo to the target lesion once every 12 hours on days&#xD;
           1-4 for a total of 8 doses.&#xD;
&#xD;
        -  Arm VII: Patients apply topical imiquimod to the target lesion once every 24 hours on&#xD;
           days 1-8 for a total of 8 doses.&#xD;
&#xD;
        -  Arm VIII: Patients apply topical placebo to the target lesion every 24 hours on days 1-8&#xD;
           for a total of 8 doses.&#xD;
&#xD;
      All patients undergo excision of the target tumor within 18-30 hours after the last topical&#xD;
      treatment.&#xD;
&#xD;
      Patients are followed at 7-14 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients (8 per treatment arm and 4 per placebo arm) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed basal cell skin cancer&#xD;
&#xD;
               -  Superficial or nodular disease&#xD;
&#xD;
               -  No aggressive disease&#xD;
&#xD;
          -  At least 1 lesion at least 7 mm in diameter that meets the following criteria:&#xD;
&#xD;
               -  Primary tumor (no recurrent or previously treated disease)&#xD;
&#xD;
               -  Located on the scalp, face (including ears), trunk, or proximal extremities&#xD;
&#xD;
               -  Qualifies for surgical excision as primary therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No evidence of a clinically significant or unstable medical condition that would&#xD;
             adversely affect blood circulation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No dermatological disease (e.g., psoriasis or eczema) at the treatment site that may&#xD;
             be exacerbated by treatment with imiquimod or interfere with examination&#xD;
&#xD;
          -  No febrile viral infection within the past 4 weeks&#xD;
&#xD;
          -  No evidence of a clinically significant or unstable medical condition that would&#xD;
             adversely affect immune function&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior interferon, interferon inducers, or immunomodulators&#xD;
&#xD;
          -  No concurrent interferon, interferon inducers, or immunomodulators&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 months since prior anticancer chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior oral or inhaled (more than 600 mcg/day for fluticasone&#xD;
             or equivalent) corticosteroids&#xD;
&#xD;
          -  More than 4 weeks since prior topical steroids to the target tumor&#xD;
&#xD;
          -  Concurrent topical steroids in non-target areas are allowed provided amount used is ≤&#xD;
             2 g of fluorinated steroids daily for &gt; 1 week or 6 g of beclomethasone for &gt; 1 week&#xD;
&#xD;
          -  No concurrent oral or inhaled corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 months since prior biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior immunosuppressive therapies&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic or investigational drugs&#xD;
&#xD;
          -  No concurrent immunosuppressive therapies&#xD;
&#xD;
          -  No other concurrent cytotoxic or investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco M. Marincola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIH - Warren Grant Magnuson Clinical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIH - Warren Grant Magnuson Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <keyword>basal cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

